Activated protein C levels in obesity and weight loss influence

Thrombosis Research

Volumn 123, Issue 5, 2009, Pages 697-700

  Solá, Eva ^a,b   Navarro, Silvia ^c   Medina, Pilar ^c   Vayá, Amparo ^c   Estellés, Amparo ^c   Hernández Mijares, Antonio ^a,b   España, Francisco ^c  

^a Endocrinology Service   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Activated C protein; Anticoagulation; Obesity; Thrombosis; Very low calorie diet

Indexed keywords

ACTIVATED PROTEIN C; PROTHROMBIN;

ADULT; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PEPTIDE FRAGMENTS; PROTEIN C; PROTHROMBIN; WEIGHT LOSS;

EID: 60449115830     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.07.017     Document Type: Article

References (26)

1. Vayá A., Mira Y., Ferrando F., Contreras M., Estellés A., España F., et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 118 (2002) 255-259
2. Pomp E.R., le Cessie S., Rosendaal F.R., and Doggen C.J. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 139 (2007) 289-296
3. Rondina M.T., Pendleton R.C., Wheeler M., and Rodgers G.M. The treatment of venous thromboembolism in special populations. Thromb Res 119 (2007) 391-402
4. Larsen T.B., Sorensen H.T., Gislum M., and Johnsen S.P. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. Thromb Res 120 (2007) 505-509
5. Avellone G., Di Garbo V., Cordova R., Cucinella G., De Simone R., Raneli G., et al. Evaluation of cardiovascular risk factors in overweight and obese subjects. Int Angiol 13 (1994) 25-29
6. Conlan M.G., Folsom A.R., Finch A., Davis C.E., Sorlie P., Marcucci G., et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70 (1993) 380-385
7. Nagai N., Hoylaerts M.F., Cleuren A.C., Van Vlijmen B.J., and Lijnen H.R. Obesity promotes injury induced femoral artery thrombosis in mice. Thromb Res 122 (2008) 549-555
8. De Pergola G., De Mitrio V., Giorgino F., et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 21 (1997) 527-535
9. Simioni P., Morboeuf O., Tognin G., et al. Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. Thromb Res 117 (2006) 523-528
10. Mezzano D., España F., Panes O., Medina P., Pais E., Marshall G., et al. Increased activation of protein C, but lower plasma levels of free, activated protein C in uraemic patients: relationship with systemic inflammation and haemostatic activation. Br J Haematol 113 (2001) 905-910
11. Navarro S., Ricart J.M., Medina P., Vayá A., Todolí J., Estellés A., et al. Activated protein C levels in Behcet's disease and risk of venous thrombosis. Br J Haematol 126 (2004) 550-556
12. Pontiroli A.E., Pizzocri P., Koprivec D., Vedani P., Marchi M., Arcelloni C., et al. Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur J Endocrinol 150 (2004) 195-200
13. Weyer C., Yudkin J.S., Stehouwer C.D., Schalkwijk C.G., Pratley R.E., and Tataranni P.A. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 161 (2002) 233-242
14. De Pergola G., and Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25 (2002) 899-904
15. España F., Zuazu I., Vicente V., Estellés A., Marco P., and Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays-enzyme levels are proportional to total protein C levels. Thromb Haemost 75 (1996) 56-61
16. Medina P., Navarro S., Estellés A., Vayá A., Woodhams B., Mira Y., et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb Haemost 91 (2004) 905-911
17. Medina P., Navarro S., Estellés A., Vayá A., Bertina R.M., and España F. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. Thromb Haemost 94 (2005) 389-394
18. Navarro S., Medina P., Mira Y., Estellés A., Villa P., Ferrando F., et al. Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation. Haematologica 93 (2008) 1-7
19. España F., Hendl S., Gilabert J., Estelles A., and Aznar J. Evaluation of two functional assays for protein C inhibitor/plasminogen activator inhibitor-3 activity. Thromb Res 70 (1993) 375-384
20. Clagett G.P., Anderson Jr. F.A., Geerts W., Heit J.A., Knudson M., Lieberman J.R., et al. Prevention of venous thromboembolism. Chest 114 S5 (1998) 531-560
21. España F., Vayá A., Mira Y., Medina P., Estellés A., Villa P., et al. Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost 86 (2001) 1368-1373
22. Woodward M., Lowe G.D., Rumley A., Tunstall-Pedoe H., Philippou H., Lane D.A., et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 97 (1997) 785-797
23. Murakami T., Horigome H., Tanaka K., Nakata Y., Katayama Y., and Matsui A. Effects of diet with or without exercise on leptin and anticoagulation protein levels in obesity. Blood Coagul Fibrinolysis 18 (2007) 389-394
24. Griffin J.H., Kojima K., Banka C.L., Curtiss L.K., and Fernandez J.A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103 (1999) 219-227
25. Vayá A., Mira Y., Ferrando F., Contreras M.T., Estellés A., España F., et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Brit J Haematol 118 (2002) 255-259
26. Deguchi H., Fernandez J.A., Pabinger I., Heit J.A., and Griffin J.H. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 97 (2001) 1907-1914